Lead Beneficiary: UNICANCER (France)
Jean-Yves Blay
Co-Lead: ZEALCO (Denmark)
Julie Gehl
Participants:
High contribution: UNICANCER, ZEALCO, Sciensano, PSCUH, IJB, IRCCS AOUBO, LU, LSMUL KK, MUW, IBB, MUL, I3S, IOCN, CSGVA, VGR
Low contribution: OOI, SAM, INC, PMSI, MSCI, BS, SoS, OUS, UGent, RM, REGIONH, RSYD, PERH,FHF, CRO-AVIANO, ISNB, IOV, REUH, VULSK, CFB, CHL, HRS, NLS, LIH, ZonMW, IPO PORTO, UKCL, OIL, UKCL, HSJD, IDIVAL, UPPSALA, NCI
Objectives
The NoE on Hi-tech medical resources focuses on technologies that work across all cancers and are highly specialised and innovative. This network aims at finding solutions allowing patients across the EU to benefit from increased knowledge and expertise and more accessible health services. As emerging resources tend to be expensive and rare, particular attention will be paid to their equal access for EU citizens.
This NoE contains 7 domains:
- Nuclear Medicine (Lead / co-lead: UNICANCER/ CSGVA)
- Radiomics (Lead / co-lead: UNICANCER/ NKUA)
- Innovative radiotherapy (Lead / co-lead: CNAO/UNICANCER)
- Innovative surgery (Lead / co-lead: OUS/OIL)
- Physical methods of ablation. (Lead / co-lead: ZEALCO/ OIL)
- Cell therapies (Lead / co-lead: UNICANCER/ IRST)
- Ex-vivo testing of agents (Lead / co-lead: UNICANCER/ NHRF)
Specific objectives of the NoE (common to all domains) are the following:
- Organize of the governance of the network
- Establish recommendations for MS regarding urgent needs and biggest gaps across Europe
- Position the network at the forefront of innovation
Specific objectives under the responsibility of each domain are:
- Support centres to better integrate innovative therapies
- Improve continuous medical education, enhancing patient and public literacy and involvement
- Ensure the visibility and the sustainability of the network through dissemination activities and evaluation criteria set-up
- Engage international and national scientific societies (e.g. ESMO, ESTRO) in these goals
- Identify and engage EU official bodies (EMA, EUnetHTA) in identifying obstacles to implementation and progress
- Address and collaborate with patient advocacy groups
Tasks
T10.1 Governance of the NoE (Task leader: UNICANCER)
T10.2 Advocacy (Task leaders: ZEALCO, UNICANCER)
T10.3 Innovation Observatory (Task leader: ZEALCO)
T10.4 Infrastructural and procedural support (Task leaders: all domain leaders)
T10.5 Education and Training (Task leaders: all domain leaders)
T10.6 Dissemination & Sustainability (Task leaders: all domain leaders)
